HEALTH

• The Centers for Medicare & Medicaid Services (CMS) has proposed a new rule to establish a permanent framework for its Medicare drug price negotiation program. • Scheduled to begin in 2029, the program focuses on negotiating and renegotiating prices for expensive, single-source drugs to reduce costs for millions of patients. • This move is significant as it aims to provide drug manufacturers with greater long-term certainty while increasing the affordability of critical medications.

• MarketBeat’s stock screener tool identified Eli Lilly and Company, Pfizer, and Abbott Laboratories as the top pharmaceutical stocks to watch on June 24th. • These companies are highlighted for their roles in the research, development, manufacturing, and sale of medicines and healthcare products. • This selection serves as a guide for investors looking to monitor high-potential assets within the pharmaceutical sector.

• First10EM's June 2026 research roundup provides a critical appraisal of a recent emergency medicine trial regarding the use of whole blood. • The study yielded statistically negative results, but the data revealed a 5% increase in mortality among patients treated with whole blood. • These findings are significant because whole blood remains an unproven therapy, suggesting that its clinical use may currently be harmful.

• The U.S. Department of Justice announced the 2026 National Health Care Fraud Takedown, charging 455 defendants for their roles in massive fraud and opioid abuse schemes. • The group of defendants includes 90 doctors and other licensed medical professionals who allegedly submitted over $6.5 billion in false health care claims. • This enforcement action is critical as the schemes caused significant patient harm, including deaths, highlighting the lethal consequences of medical fraud.

• White House deputy assistant for domestic policy Heidi Overton is reportedly among the final candidates being considered to lead the Food and Drug Administration (FDA). • Overton is a medical doctor who holds a doctorate in clinical investigation from Johns Hopkins University, bringing significant medical and policy expertise to the role. • This potential appointment is critical as the FDA head oversees the safety and efficacy of pharmaceuticals and food products across the United States.

• The U.S. Department of Health and Human Services (HHS) has launched a coordinated, department-wide initiative to restore American leadership in clinical research. • The ONC is working to integrate clinical trial notifications into electronic health records to connect eligible patients with research opportunities during routine care. • ARPA-H is implementing modernization programs, including THRIVE and CATALYST, which utilize AI and machine learning to optimize dosing and predict safety before patient enrollment.

• The author identifies four early-stage medical breakthroughs currently in clinical trials that could potentially treat major killers like cancer, heart disease, and neurodegenerative diseases. • While acknowledging that many promising medical ideas fail during development, these specific advances are being monitored with cautious optimism by leading research institutions. • These breakthroughs are highlighted as the most likely to significantly impact human health over the next decade, particularly in addressing heart disease, the world's leading cause of death.

• The author challenges the public health establishment's claim that universal vaccination is the essential tool for preventing epidemics like Covid-19, polio, and measles. • The piece argues that while medical science is effective at a micro level, a macro-level analysis of epidemic curves is necessary to understand disease trajectories. • This perspective suggests that the necessity of universal vaccination is not supported by randomized controlled trials or the historical data of epidemic curves.

• Former leaders from the FDA, CDC, and NIH convened at the BIO International Convention to discuss the dismantling of the Department of Health and Human Services under the Trump administration. • The panel focused on the collapse of existing US public health structures and the urgent need to rebuild a more effective system. • Experts warned that immediate action is required as infectious disease outbreaks, including Ebola and hantavirus, are becoming increasingly common.

• The SODa-BIC Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group have published new research in The New England Journal of Medicine. • The study, identified by DOI:10.1056/NEJMoa2600526, focuses on clinical trials conducted within intensive care settings. • This publication provides critical data on medical interventions that may influence patient outcomes and standard care protocols in critical care medicine.

• The FDA has launched a new initiative aimed at resetting the drug review process to accelerate the development of new medications. • A primary goal of the program is to boost the number of domestic clinical trials, reducing reliance on overseas data and speeding up patient access to therapies. • This shift matters as the agency seeks to streamline regulatory hurdles and improve the efficiency of bringing innovative treatments to the U.S. market.

• PwC reports that health services M&A activity remains active in 2026, with overall deal value increasing compared to the first half of 2025. • Despite higher values, deal volume is slowing as buyers become more selective due to reimbursement pressures and policy uncertainty. • Financial risks are rising for providers as Medicaid cuts from the “Big Beautiful Bill” and higher ACA exchange costs are expected to increase the number of uninsured patients.

• The US Administration is restructuring the systems supporting PEPFAR and global health security, shifting its engagement strategy toward regulatory influence over long-term public health partnerships. • Concerns are rising that increased political oversight and the deconstruction of international collaborations may undermine the NIH's scientific infrastructure and its history of HIV research and vaccine development. • In a move toward regulatory cooperation, the US Food and Drug Administration (FDA) and the African Medicines Agency (AMA) signed a Memorandum of Understanding (MoU) to establish a shared framework for information sharing.

• The FDA has accepted Roche's application to use the combination of Lunsumio and Polivy for patient treatment. • This regulatory milestone is part of Roche's effort to expand the indications and clinical utility of these existing in-market products. • The development matters as it potentially provides a new therapeutic option for patients requiring this specific drug combination.

• The ICH has introduced a new standardized framework for clinical trial protocols consisting of a harmonized guideline, a protocol template, and a technical specification for electronic exchange. • These documents apply to all phases and therapeutic areas of interventional clinical trials, including pharmaceuticals, biologics, vaccines, and cell or gene therapy products. • This initiative matters as it streamlines the format and content of protocols, facilitating more efficient data exchange and regulatory consistency across global jurisdictions.

• The article alleges a cover-up regarding the origins of SARS-CoV-2, specifically highlighting the role of the DEFUSE project. • This project involved scientists from the U.S., foreign entities, and the Wuhan Institute of Virology who proposed modifying spike proteins of coronaviruses to model disease spread among U.S. Pacific forces. • The research is described as high-risk, "gain-of-function" dual-use research focused on vaccine vectors and dispersal development.

• U.S. Health Secretary Robert F. Kennedy Jr. announced over $700 million in new funding opportunities on Wednesday to address mental illness, addiction, and homelessness. • The financial package includes $238.6 million for the 988 Suicide and Crisis Lifeline and $223.1 million for Certified Community Behavioral Health Clinics. • Additional allocations consist of $80 million for substance use prevention and recovery programs, alongside more than $70 million for general mental health services.

• The FDA has granted a new indication for the drug Tzield, expanding its use to patients who have already progressed to Stage 3 type 1 diabetes. • This latest approval aims to preserve residual beta cell function, building on previous expansions in April 2026 that extended the drug's use to children as young as one year old. • The decision was based on the PROTECT trial, which demonstrated a statistically significant effect on C-peptide, a surrogate endpoint used to predict clinical benefit.